JP2021522798A5 - - Google Patents
Info
- Publication number
- JP2021522798A5 JP2021522798A5 JP2020561821A JP2020561821A JP2021522798A5 JP 2021522798 A5 JP2021522798 A5 JP 2021522798A5 JP 2020561821 A JP2020561821 A JP 2020561821A JP 2020561821 A JP2020561821 A JP 2020561821A JP 2021522798 A5 JP2021522798 A5 JP 2021522798A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition according
- express
- antigen
- hiv
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000389A JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666665P | 2018-05-03 | 2018-05-03 | |
| US62/666,665 | 2018-05-03 | ||
| US201862666965P | 2018-05-04 | 2018-05-04 | |
| US62/666,965 | 2018-05-04 | ||
| PCT/US2019/030721 WO2019213610A1 (en) | 2018-05-03 | 2019-05-03 | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Division JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522798A JP2021522798A (ja) | 2021-09-02 |
| JP2021522798A5 true JP2021522798A5 (https=) | 2022-05-09 |
| JPWO2019213610A5 JPWO2019213610A5 (https=) | 2022-05-09 |
Family
ID=68386134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561821A Ceased JP2021522798A (ja) | 2018-05-03 | 2019-05-03 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210230548A1 (https=) |
| EP (1) | EP3788061A4 (https=) |
| JP (2) | JP2021522798A (https=) |
| KR (1) | KR20210005240A (https=) |
| CN (1) | CN112292390A (https=) |
| AU (1) | AU2019262218B2 (https=) |
| BR (1) | BR112020022010A2 (https=) |
| CA (1) | CA3099342A1 (https=) |
| CO (1) | CO2020015168A2 (https=) |
| MX (1) | MX2020011697A (https=) |
| NZ (1) | NZ770183A (https=) |
| SG (1) | SG11202010763VA (https=) |
| WO (1) | WO2019213610A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
| CA2841356C (en) | 2011-07-11 | 2022-03-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| EP3706766A4 (en) * | 2017-11-09 | 2021-08-18 | Sangamo Therapeutics, Inc. | GENETIC MODIFICATION OF THE CYTOCINE INDUCTIBLE SH2-CONTAINING PROTEIN (CISH) GENE |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| IL278723B2 (en) | 2018-05-16 | 2024-07-01 | Res Inst Nationwide Childrens Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020205359A1 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Methods for production of car-nk cells and use thereof |
| JP7629414B2 (ja) * | 2019-06-04 | 2025-02-13 | ンカルタ・インコーポレイテッド | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| US12195723B2 (en) * | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| KR20220108793A (ko) * | 2019-11-27 | 2022-08-03 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Msc 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집 |
| US20220389383A1 (en) * | 2019-11-27 | 2022-12-08 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and crispr gene editing of nk cells |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| US20230060351A1 (en) * | 2020-01-08 | 2023-03-02 | Board Of Regents, The University Of Texas System | A method of engineering natural killer cells to target cd70-positive tumors |
| WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
| CN113913458A (zh) * | 2020-07-09 | 2022-01-11 | 杭州优凯瑞医药科技有限公司 | 非病毒方法制备稳定高表达嵌合受体的nk细胞 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| JP2023552998A (ja) * | 2020-12-03 | 2023-12-20 | ンカルタ・インコーポレイテッド | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
| JP2023552895A (ja) | 2020-12-15 | 2023-12-19 | ユニフェルシテイト アントウェルペン | Ｃｄ７０をターゲティングする細胞ベースの治療剤 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| AR124837A1 (es) | 2021-02-09 | 2023-05-10 | Millennium Pharm Inc | Métodos y composiciones para congelar y descongelar células de mamíferos |
| CN113005151A (zh) * | 2021-03-12 | 2021-06-22 | 广东药科大学 | 一种kdr-car-nk细胞的制备方法及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| IL307940A (en) | 2021-04-26 | 2023-12-01 | Millennium Pharm Inc | Anti-ADGRE2 antibodies and their uses |
| WO2022242700A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified nk cells and uses thereof |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
| IL311665A (en) * | 2021-10-01 | 2024-05-01 | Univ Texas | Antibody loaded immune cells and methods for use in cancer treatment |
| WO2023062113A1 (en) * | 2021-10-15 | 2023-04-20 | Miltenyi Biotec B.V. & Co. KG | Method for the generation of genetically modified nk cells |
| WO2023070079A1 (en) * | 2021-10-21 | 2023-04-27 | Board Of Regents, The University Of Texas System | Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof |
| AU2022381757A1 (en) * | 2021-11-04 | 2024-05-09 | Saliogen Therapeutics, Inc. | Immune cells with chimeric antigen receptors or chimeric autoantibody receptors |
| US20230149464A1 (en) | 2021-11-18 | 2023-05-18 | Janssen Biotech, Inc. | Feeder free cell culture methods for expanding natural killer cell preparations |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| AR130860A1 (es) * | 2022-10-25 | 2025-01-29 | Takeda Pharmaceuticals Co | Composiciones de linfocitos nk del receptor quimérico adgre2 y métodos de uso |
| CN120091827A (zh) * | 2022-11-10 | 2025-06-03 | 昂克医疗有限公司 | 使用免疫调节药物的联合疗法 |
| CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
| CN115948344A (zh) * | 2023-02-10 | 2023-04-11 | 上海交通大学 | 嵌合抗原受体nk细胞、制备方法及其用途 |
| CN116731972A (zh) * | 2023-02-10 | 2023-09-12 | 上海交通大学 | 嵌合抗原受体t细胞、制备方法及其用途 |
| AU2024244976A1 (en) * | 2023-03-24 | 2025-09-25 | Board Of Regents, The University Of Texas System | Engineered natural killer cells with enhanced antitumor memory responses |
| US20240358758A1 (en) * | 2023-04-07 | 2024-10-31 | Nkarta, Inc. | Methods for treatment of autoimmune diseases |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) * | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487800B2 (en) * | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| ES2652666T3 (es) * | 2011-12-22 | 2018-02-05 | Mogam Biotechnology Institute | Procedimiento de producción de linfocitos citolíticos naturales, linfocitos citolíticos naturales producidos de este modo y composición para el tratamiento de cánceres y enfermedades infecciosas que contienen los mismos |
| GB2592821B (en) * | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| ES2952064T3 (es) * | 2015-12-16 | 2023-10-26 | Walter & Eliza Hall Inst Medical Res | Inhibición de la proteína SH2 inducida por citocinas en células NK |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| AU2017207936A1 (en) * | 2016-01-15 | 2018-07-26 | Etubics Corporation | Methods and compositions for T-cell immunotherapy |
| CN109890408A (zh) * | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
| CA3041831A1 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of making genetically modified cells |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2020205359A1 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Methods for production of car-nk cells and use thereof |
-
2019
- 2019-05-03 MX MX2020011697A patent/MX2020011697A/es unknown
- 2019-05-03 BR BR112020022010-8A patent/BR112020022010A2/pt unknown
- 2019-05-03 KR KR1020207034764A patent/KR20210005240A/ko not_active Ceased
- 2019-05-03 CA CA3099342A patent/CA3099342A1/en active Pending
- 2019-05-03 NZ NZ770183A patent/NZ770183A/en unknown
- 2019-05-03 JP JP2020561821A patent/JP2021522798A/ja not_active Ceased
- 2019-05-03 SG SG11202010763VA patent/SG11202010763VA/en unknown
- 2019-05-03 AU AU2019262218A patent/AU2019262218B2/en active Active
- 2019-05-03 EP EP19795874.7A patent/EP3788061A4/en active Pending
- 2019-05-03 CN CN201980037453.2A patent/CN112292390A/zh active Pending
- 2019-05-03 WO PCT/US2019/030721 patent/WO2019213610A1/en not_active Ceased
- 2019-05-03 US US17/050,775 patent/US20210230548A1/en active Pending
-
2020
- 2020-12-02 CO CONC2020/0015168A patent/CO2020015168A2/es unknown
-
2024
- 2024-01-05 JP JP2024000389A patent/JP2024045179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522798A5 (https=) | ||
| JPWO2019213610A5 (https=) | ||
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Ames et al. | Advantages and clinical applications of natural killer cells in cancer immunotherapy | |
| CN108025024B (zh) | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 | |
| US20240325450A1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| CN113286811A (zh) | 改善过继性细胞疗法的效力和安全性 | |
| Bialkowski et al. | Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours | |
| EP1434596B1 (en) | Enhancement of immune responses by agonist 4-1bb-antibodies | |
| JP2016539929A5 (https=) | ||
| JP2021501604A5 (https=) | ||
| US20210113691A1 (en) | Use of Triplex CMV Vaccine in CAR T Cell Therapy | |
| Hu et al. | Natural killer cell-based immunotherapy for cancer: advances and prospects | |
| JPWO2020088631A5 (https=) | ||
| WO2017219150A1 (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
| CN115768879A (zh) | 用于培养细胞的方法 | |
| CN110404061B (zh) | 改进的t细胞治疗方法 | |
| Mazza et al. | Prospects for development of induced pluripotent stem cell-derived CAR-targeted immunotherapies | |
| CN111683971A (zh) | 医药重组受体组成物及方法 | |
| Letessier et al. | Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer | |
| WO2021141986A1 (en) | Chimeric gmcsf-il18 receptor | |
| TW202309269A (zh) | 重組抗原呈現細胞 | |
| Yee | Adoptive therapy using antigen-specific T-cell clones | |
| CN110621693A (zh) | 抗原受体及其用途 | |
| US20160235827A1 (en) | Placental compositions for stimulation of immunity to pd-l1 |